SPECIAL REPORT
Crowdstrike, Natera Executives Sell Tens of Millions in Stock
Four separate insider sales filed this week total more than $68 million across two companies.
Executive takeaway
Crowdstrike president Michael Sentonas sold $64.2 million in stock, the largest of four insider sales disclosed this week that also included Natera's CEO, its president, and Spyre Therapeutics' chief legal officer.
A cluster of insider stock sales surfaced in wire filings. Crowdstrike president Michael Sentonas sold $64.2 million in shares, by far the largest transaction. At Natera, CEO Steven Chapman sold $526,000 in common stock and president Solomon Moshkevich sold $1.24 million in shares. Spyre Therapeutics' chief legal officer separately sold $2.63 million in shares.
Insider sales are routine and do not by themselves signal a view on a company's prospects — many executives sell on a pre-set schedule to diversify holdings or cover tax bills. But the size of the Crowdstrike sale, more than $64 million from one executive in a single disclosure, is large enough to draw attention even against that backdrop.
None of the filings disclose whether the sales were made under 10b5-1 trading plans, which are set up in advance and are not driven by current material information. That detail would change how much weight investors should put on the timing.
What would change this view
If subsequent filings confirm these were pre-scheduled 10b5-1 sales rather than discretionary trades, the sales would carry far less signal about executive sentiment.
Wire sources cited
- Investing.com — All NewsNatera president Solomon Moshkevich sells $1.24m in sharesExternal ↗
- Investing.com — All NewsCrowdstrike president Michael Sentonas sells $64.2 million in stockExternal ↗
- Investing.com — All NewsSpyre Therapeutics’ chief legal officer sells $2.63m in sharesExternal ↗
- Investing.com — All NewsNatera CEO Steven Chapman sells $526k in common stockExternal ↗
Produced automatically by the INDY NEWS Desk from the public wire sources cited above, and checked against them before publication. Market commentary, not investment advice.